Abraxis BioScience
E932802
Abraxis BioScience was a biopharmaceutical company best known for developing the cancer drug Abraxane and focusing on nanoparticle-based chemotherapy treatments.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Abraxis BioScience canonical | 1 |
Statements (38)
| Predicate | Object |
|---|---|
| instanceOf | biopharmaceutical company ⓘ |
| abbreviation | formerly traded as ABII on NASDAQ ⓘ |
| acquiredBy | Celgene NERFINISHED ⓘ |
| acquisitionDate | 2010 ⓘ |
| acquisitionValue | approximately 2.9 billion US dollars ⓘ |
| country |
United States of America
ⓘ
surface form:
United States
|
| developedFor |
treatment of metastatic breast cancer
ⓘ
treatment of non-small cell lung cancer ⓘ treatment of pancreatic cancer ⓘ |
| developedTechnology | nab-paclitaxel formulation ⓘ |
| dissolved | 2010 ⓘ |
| focus | nanoparticle-based chemotherapy ⓘ |
| foundedBy | Patrick Soon-Shiong NERFINISHED ⓘ |
| headquartersLocation | Los Angeles, California NERFINISHED ⓘ |
| industry |
biotechnology
ⓘ
pharmaceuticals ⓘ |
| keyPerson | Patrick Soon-Shiong NERFINISHED ⓘ |
| knownFor |
development of Abraxane
ⓘ
nanoparticle albumin-bound (nab) technology ⓘ |
| marketedBrand | Abraxane NERFINISHED ⓘ |
| notableDrug | Abraxane NERFINISHED ⓘ |
| parentCompanyAfterAcquisition | Celgene NERFINISHED ⓘ |
| predecessor |
American BioScience
NERFINISHED
ⓘ
American Pharmaceutical Partners NERFINISHED ⓘ |
| productDeveloped | Abraxane NERFINISHED ⓘ |
| regulatoryApproval |
U.S. FDA approval for Abraxane in metastatic breast cancer
ⓘ
U.S. FDA approval for Abraxane in non-small cell lung cancer ⓘ U.S. FDA approval for Abraxane in pancreatic cancer ⓘ |
| researchArea |
nanoparticle therapeutics
ⓘ
targeted drug delivery ⓘ |
| specialization |
nanomedicine
ⓘ
oncology therapeutics ⓘ |
| status | defunct ⓘ |
| successor | Celgene NERFINISHED ⓘ |
| technologyBasis | albumin-bound nanoparticle delivery ⓘ |
| therapeuticArea |
cancer
ⓘ
oncology ⓘ |
| tradedAs | NASDAQ:ABII NERFINISHED ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.